Form 4: Ligand Pharmaceuticals CEO Todd Davis Reports Stock and Option Awards
SEC Form 4 Filing
CEO Todd Davis reports acquisition of restricted stock units and stock options in Ligand Pharmaceuticals.
Summary
- Todd C. Davis, CEO of Ligand Pharmaceuticals, reported the acquisition of 21,382 shares of common stock in the form of restricted stock units (RSUs) and 93,476 stock options on March 4, 2025.
- The RSUs vest in three equal annual installments starting February 15, 2026, and the stock options vest beginning six months after the grant date, followed by 42 equal monthly installments.
- Following the reported transactions, Davis directly owns 151,724 shares of Ligand Pharmaceuticals common stock and 93,476 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices, aligning management with shareholder interests.
Positives
- The grant of RSUs and stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
- The vesting schedules for both RSUs and stock options encourage long-term commitment from the CEO.
Industry Context
Executive compensation through stock options and RSUs is a common practice in the pharmaceutical industry to align management's interests with shareholder value and incentivize long-term performance.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry, often benchmarked against peer companies of similar size and market capitalization.
- Vesting schedules for RSUs, typically ranging from three to five years, are designed to retain key executives and align their interests with the long-term success of the company.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity-based compensation strategies for their executives.
Stakeholder Impact
- The stock and option awards could positively impact shareholders by incentivizing the CEO to improve company performance.
- Employees may view the CEO's equity stake as a positive sign of leadership commitment.
Key Dates
| Date | Description |
|---|---|
| 03/04/2025 | Date of earliest transaction: Acquisition of RSUs and stock options. |
| 03/04/2025 | Date of stock option grant. |
| 03/06/2025 | Date of signature on the Form 4. |
| 02/15/2026 | First vesting date for RSUs. |
| 02/15/2027 | Second vesting date for RSUs. |
| 02/15/2028 | Third vesting date for RSUs. |
| 03/04/2035 | Expiration date for stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.